Do New Medical Devices Really Work? From Scalp Cooling and Artificial Pancreas Systems to Sleep Apnea Treatment

New Medical Devices: Efficacy, Limitations, and Principles for Selection

Bottom line

Scalp cooling, hybrid closed-loop artificial pancreas systems, and sleep apnea treatment devices are each supported by evidence. They are tools designed for specific problems, however; benefit is not a guarantee of success, nor can these devices replace condition-appropriate selection and continued follow-up. (PMID: 38936283; PMID: 41527459; PMID: 42110829)

Start with the clinical problem, not the pursuit of “new”

Medical devices often attract attention through intuitive engineering concepts: cooling the scalp, enabling a sensor and pump to communicate, or keeping the airway open during sleep. The central issue in evaluating them, however, is not how advanced the machine appears. It is whether the device genuinely reduces outcomes that matter to patients in clinical practice and whether its burden of use is manageable. The same device may work very well for some people yet prove difficult for others to continue because of discomfort, operational demands, or differences in their condition.

Professor Lin’s original articles introduced these technologies in the context of the evidence and stage of product development at the time. When reading them today, we should preserve that historical context. If later meta-analyses have clarified the magnitude of benefit, this should be understood as updated literature and the evolution of science—not as rewriting what the professor originally said.

Scalp cooling: It can reduce chemotherapy-induced hair loss, but not everyone retains all their hair

The basic premise of scalp cooling is to lower scalp temperature during chemotherapy infusion. This constricts blood vessels, reduces blood flow and drug exposure to the hair follicles, and lowers follicular cell metabolism. Subsequent research supports this mechanism and also indicates that low temperature itself may exert a temperature-dependent cytoprotective effect. (PMID: 42122147; PMID: 40693274)

Regarding efficacy, among evaluable participants in the randomized SCALP trial, some patients in the cooling group retained their hair, whereas none did in the control group. This is consistent with the findings cited by Professor Lin, and later systematic reviews also support the conclusion that scalp cooling can reduce chemotherapy-induced alopecia. (PMID: 28196254; PMID: 38936283)

“Reduced hair loss,” however, must not be translated into “no hair loss.” Outcomes may vary with the chemotherapy regimen, the patient’s condition, and the treatment process. Tolerability must also be described candidly. Later pooled evidence indicates that most patients can continue treatment, but chills and headaches are not uncommon. Professor Lin’s account—that patients initially felt cold and gradually adapted—therefore reflects the experience of many patients. With the updated literature, the more complete formulation is that overall acceptability is reasonable, although some people discontinue treatment because of discomfort. (PMID: 41269388)

Regulatory approval must likewise be placed on a timeline. When Professor Lin’s original article was published, he described DigniCap as the only scalp-cooling system then approved by the US FDA and Paxman as still awaiting approval. That accurately reflected the situation at the time. Such a statement was “correct at that point in time” and should not be treated as a current product list. (PMID: 28976026; PMID: 41269388)

Hybrid closed-loop artificial pancreas: Automated adjustment does not mean completely hands-off care

Type 1 diabetes results from autoimmune destruction of pancreatic beta cells, causing insulin deficiency, and it is often diagnosed during adolescence. Professor Lin’s explanation of its pathophysiology and epidemiology is consistent with subsequent authoritative literature. (PMID: 41697686)

The MiniMed 670G is a hybrid closed-loop system: a continuous glucose sensor collects data, and a control system then coordinates the insulin pump to adjust delivery. This substantially automates tasks that traditionally required repeated measurement and adjustment, and it has become an important development in care for type 1 diabetes. (PMID: 41024422; PMID: 40590465)

The key limitation lies in the word “hybrid.” Patients must still provide information at mealtimes or manage mealtime doses, so this is not an artificial pancreas that operates without any human involvement. It is more accurate to understand the system as reducing daily burden and helping improve glycemic control than to assume that patients no longer need to manage their diabetes. (PMID: 41024422)

Subsequent meta-analyses show that hybrid closed-loop systems improve glycemic control and reduce time in hyperglycemia compared with sensor-augmented pumps. Other studies also support their efficacy and safety. Professor Lin’s central judgment in describing this as an effective new therapy is therefore consistent with the literature today. (PMID: 41527459; PMID: 42410321)

Sleep apnea: Standard therapy and alternative devices each have a role

For obstructive sleep apnea, CPAP remains the recognized standard and first-line treatment. It supplies continuous positive pressure during sleep to help keep the upper airway open. This position is consistent with Professor Lin’s description of CPAP as the gold standard. (PMID: 42110829; PMID: 42200975)

The importance of treatment extends beyond reducing snoring. Untreated obstructive sleep apnea is associated with hypertension, arrhythmias, coronary heart disease, myocardial infarction, stroke, and the risk of death. It therefore cannot be dismissed as merely a noise problem affecting one’s bed partner. (PMID: 42200975; PMID: 42110829; PMID: 41951895)

The challenge with CPAP is sustained use. Patients must sleep while wearing a nasal interface or mask connected to tubing, and intolerance and nonadherence are genuine clinical obstacles. Professor Lin noted that acceptance was suboptimal, which is directionally consistent with the literature. A single percentage, however, may vary with study definitions, follow-up methods, and populations. The more reliable emphasis is to address mask fit, pressure, and tolerability rather than compress every difficulty with use into one fixed number. (PMID: 42110829; PMID: 42166156)

For appropriately evaluated patients who cannot tolerate CPAP, hypoglossal nerve stimulation offers another pathway. Research supports its ability to reduce obstructive respiratory events and improve overnight blood oxygenation. Yet the overall benefit observed in later systematic reviews does not universally reach the striking magnitude reported in early studies or the best individual cases. This is a calibration brought about by scientific progress: the direction of benefit remains valid, but a specific result should not be presented as a guaranteed average outcome for everyone. (PMID: 42166156; PMID: 42519992; PMID: 42344809)

How to discuss these options with healthcare professionals

When considering a new device, first clarify the goal: reducing chemotherapy-induced hair loss, improving glycemic control, or maintaining airway patency during sleep. Then ask whether your circumstances match the populations studied, what common discomforts may occur, what daily tasks the device requires, and what alternatives are available if it does not work as expected. The value of a device comes from appropriate selection, correct use, follow-up, and adjustment—not from the words “new” or “smart” in its name.

In summary, Professor Lin’s account of the core principles and clinical direction of these devices is largely supported by subsequent evidence. Where the literature has been updated, it mainly adds clearer boundaries concerning tolerability, human involvement, and the average magnitude of benefit. Explaining those boundaries allows patients to avoid missing useful tools without being led by excessive promises.